44 results about "Bacillus fragilis" patented technology

The invention relates to the technical field of microorganisms, in particular to application of pediococcus acidilactici. The pediococcus acidilactici TG005 is preserved in the China Center for Type Culture Collection on June 24, 2024, the preservation number is CCTCC NO: M 20241349, and the preservation address is Wuhan University, Wuhan, China. The pediococcus acidilactici TG005 provided by the invention is a multifunctional probiotic strain, is obtained by screening from domestic healthy human excrement samples, and has good application safety and functional adaptability; the strain can reduce the cholesterol level and prevent cardiovascular diseases; uric acid precursor substances are degraded, uric acid generation is reduced, and hyperuricemia and related diseases are prevented; pathogenic bacteria with fusobacterium nucleatum and bacteroides fragilis can be inhibited, and colorectal cancer is prevented; when being used as a probiotic additive for preparing medicines for degrading cholesterol, preventing cardiovascular diseases caused by high cholesterol, preventing hyperuricemia, colorectal cancer and the like, the lactobacillus plantarum has a wide application prospect.

The invention discloses bacteroides fragilis capable of converting ginsenoside Rb1 and ginsenoside Rd to obtain rare saponin aescilloside XVII and ginsenoside F2 and application of the bacteroides fragilis CMLF03. The bacteroides fragilis CMLF03 is preserved in China General Microbiological Culture Collection Center, the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC NO. The preservation date is January 25, 2024, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO.41094. The invention solves the problem of low conversion rate of the existing method for converting ginsenoside into rare ginsenoside. The bacteroides fragilis CMLF03 disclosed by the invention can be used for converting ginsenoside Rb1 and ginsenoside Rd to obtain rare saponin aescin XVII and ginsenoside F2.

The invention belongs to the field of molecular biological detection, and provides a joint detection composition which is mainly used for detecting related pathogens by using a multiple fluorescent PCR (Polymerase Chain Reaction) analysis method. Therefore, at least four of staphylococcus aureus, staphylococcus capitis, bacteroides fragilis, streptococcus agalactiae, streptococcus salivarius and staphylococcus hominis are detected and distinguished in a single-tube reaction system at the same time. Meanwhile, the detection sensitivity of the composition is higher and reaches 200 copies / mL, and the detection is more accurate.

Different animal model tests prove that the bacteroides fragilis, especially viable bacteria, lysate, inactivated bacteria, extracts and the like of the bacteroides fragilis ZY-312 with the preservation number of CGMCC No.10685 and the bacteroides fragilis NCTC 9343 have the effects of improving and treating the functional gastrointestinal diseases, especially functional dyspepsia and irritable bowel syndrome. For functional dyspepsia, bacteroides fragilis can effectively improve weight loss, anorexia, visceral hypersensitivity and gastric motility disorder caused by functional dyspepsia. For irritable bowel syndrome, bacteroides fragilis can effectively improve diarrhea symptoms and reduce intestinal sensitivity.

The application provides application of Bacteroides fragilis in improving and / or treating diarrhea. It is proved by different mouse diarrhea model tests that the Bacteroides fragilis ZY-312 with the preservation number of CGMCC No. 10685 or inactivated bacteria thereof have the effects of improving and treating diarrhea. The inactivated bacteria powder of the Bacteroides fragilis has better effects on improving infectious diarrhea or non-infectious diarrhea under different concentration formulations, has no side effects on the body, has a good edible and application prospect, and provides a good product suitable for human consumption for health care and improvement of diarrhea.

The present invention discloses an intestinal microbiota Bacteroides fragilis toxin-neutralizing nanobody and its application. By deeply studying the enterotoxigenic Bacteroides fragilis and the toxin BFT secreted by it in the bodies of patients with colorectal cancer and breast cancer, nanobodies against BFT are expressed by phage display technology; nanobodies with high binding affinity to the antigen are screened out through biopanning technology; a nanobody with the ability to neutralize the toxicity of BFT, also known as Nb2.43, is obtained. The present invention expresses and optimizes to obtain a BFT nanobody protein with high affinity, stability and uniformity, opening up a new field for the treatment of colorectal cancer and breast cancer with nanobodies targeting BFT, and having good research value and application prospects.

The invention discloses an osthole derivative shown in a general formula 3 in the technical field of organic chemistry. The substituent group R of # imgabs0 is nitroimidazole, substituted nitroimidazole, nitrobenzimidazole or nitrotriazole; and n is 3 or 4. The invention further relates to application of the compound shown in the general formula 3 to preparation of antibacterial drugs independently or in combination with antibacterial active ingredients, and bacteria comprise any one of bacteroides fragilis, anaerobic peptostreptococcus, staphylococcus aureus and escherichia coli.

Provided are methods for producing polysaccharides in bacteria by expressing in a bacterium one or more coding sequences selected from the group consisting of a pglF dehydrogenase coding sequence, a wbpP UDP-N-acetyl-d-glucosamine C4 epimerase coding sequence, a wcfR aminotransferase coding sequence, and a wcfS phospho-glycosyltransferase coding sequence, a wcfQ glycosyltransferase coding sequence, a wcfO pyruvyltransferase coding sequence, a wcfP glycosyltransferase coding sequence, a wcfM UDP-galactopyranose mutase coding sequence, a wcfN glycosyltransferase coding sequence, a wza polysaccharide export protein coding sequence, a wzx fippase coding sequence, a wzy polymerase coding sequence, and a wzz coding sequence, wherein at least one of the coding sequences is heterologous to the bacterium. Also provided are expression cassettes with one or more of the disclosed coding sequences, recombinant bacteria that harbor one or more of the expression cassettes, and methods for producing immunogenic compositions using the polysaccharides produced by the recombinant bacteria.

The invention provides application of bacteroides fragilis 839 in preparation of health food, food composition or medicine for improving hepatotoxicity caused by antituberculosis medicine. The bacteroides fragilis BF839 is adopted for the first time in the world to improve the mouse hepatotoxicity caused by the antituberculous drug, and it is found that the bacteroides fragilis BF839 can reduce or relieve the mouse hepatotoxicity caused by the antituberculous drug and has the advantages of being efficient and safe.

The invention provides an osteoporosis diagnostic marker composition and application thereof in preparation of an osteoporosis diagnostic product, and relates to the technical field of biology. According to the invention, the osteoporosis diagnostic marker composition comprising at least one of Kotill campylobacter, Lactobacillus fragilis, Streptococcus parahaemolyticus, Porphyromonas sp and Bacteroides fragilis is applied to the preparation of the osteoporosis diagnostic product, so that the breakthrough on the traditional detection means dependent on bone mineral density is realized; and a molecular-level, early-stage and non-invasive risk early warning means is provided.

A microorganism containing Bacteroides fragilis genes is used as an active ingredient in the preparation of pharmaceuticals, medical devices, or food for treating optic nerve damage. This delivers Bacteroides fragilis (or its functional components) into the gastrointestinal tract, which helps maintain the number of retinal ganglion cells and the thickness of the retinal nerve fiber layer, inhibits the activation of retinal microglia, inhibits the activation of retinal inflammatory pathways and the expression of inflammatory mediators, thereby protecting visual function.

The microorganism contains the bacteroides fragilis gene, and the bacteroides fragilis gene is used as an active ingredient to be applied to preparation of medicine or food for treating optic nerve damage, the bacteroides fragilis (or functional components thereof) is delivered to gastrointestinal tracts, the number of retinal ganglion cells and the thickness of a retinal nerve fiber layer can be maintained, activation of retinal microglia cells is inhibited, and optic nerve damage is inhibited. Retina inflammation pathway activation and inflammatory mediator expression are inhibited, so that the visual function is protected.

A composition for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes a Siphoviridae bacteriophage (Bac-FRP-4) having an ability to lyse the enterotoxigenic Bacteroides fragilis cells and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes administering to a subject a Siphoviridae bacteriophage and lysing the enterotoxigenic Bacteroides fragilis cells by the Siphoviridae bacteriophage.

The invention discloses a microbial marker for treating recurrent clostridium difficile infection based on coprophilous fungus transplantation and a screening method of the microbial marker. The microbial marker comprises the following components: Dorea longigena, Alistipes putredinis, Citrobacter farmeri, Coprococcos, Eubacter coprostanoliganes, Agatrobacter rectas, Dorea foetida, Blauria obbe, Klebsiella foetida, Blauria foetida, Blauria ovaticus and Gemmigerformation. The microbial marker comprises the following components: Dorea longigena, Alistipes putredinis, Citrobacter farmeri, Citrobacter coprostanoliganes, Citrobacter rectas, according to the invention, through metagenome sequencing and a machine learning algorithm, key microbial markers significantly related to recurrent clostridium difficile symptom improvement in the coprophilous fungus transplantation treatment process are screened out, and a scientific basis and a standardized scheme are provided for coprophilous fungus transplantation treatment of recurrent clostridium difficile infection.

The present invention relates to the application of creatmycin in inhibiting gastrointestinal tract pathogenic bacteria, and the gastrointestinal tract pathogenic bacteria include but are not limited to: Helicobacter pylori, Clostridium difficile, Bacteroides fragilis, Escherichia fergusonii, Clostridium sporogenes.

This invention discloses novel specific molecular targets for *Bacteroides fragilis* and its BFS17, along with a rapid detection method. The molecular target nucleotide sequence of *Bacteroides fragilis* is shown in SEQ ID NO.1, and the molecular target nucleotide sequence of *Bacteroides fragilis* BFS17 is shown in SEQ ID NO.2. This invention uses a pan-genomic approach to obtain the specific core genes of *Bacteroides fragilis* and the probiotic strain *Bacteroides fragilis* BFS17, and designs characteristic primers that can sensitively detect *Bacteroides fragilis* and the probiotic strain *Bacteroides fragilis* BFS17. Furthermore, this method can rapidly and easily distinguish *Bacteroides fragilis*, the probiotic strain *Bacteroides fragilis* BFS17, and other microbial strains. This invention has the advantages of being simple and rapid to operate, highly specific, quantifiable, and inexpensive.

A composition for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes a Siphoviridae bacteriophage (Bac-FRP-5) having an ability to lyse the enterotoxigenic Bacteroides fragilis cells and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes administering to a subject a Siphoviridae bacteriophage and lysing the enterotoxigenic Bacteroides fragilis cells by the Siphoviridae bacteriophage.

The invention discloses application of alpha-caryophyllene in preparation of a medicine for treating colorectal cancer. The alpha-caryophyllene can regulate the abundance of bacteroides fragilis capable of producing enterotoxin, inhibit the proliferation and migration ability of colorectal tumor cells mediated by bacteroides fragilis capable of producing enterotoxin, and can slow down the progress of colon cancer by improving the abundance of intestinal microorganisms. The invention discloses a new application of alpha-caryophyllene in preparation of medicines for treating colorectal cancer, and provides a new application direction. Alpha-caryophyllene is a natural active component, has low side effects and is easily accepted clinically. The invention provides new scientific research evidence for research and development of medicines for treating colorectal cancer, and has important clinical application value and development value.

The invention belongs to the technical field of biology, and particularly relates to a fucosyltransferase mutant and application thereof. According to the invention, a plurality of mutation sites of alpha-1, 2-fucosyltransferase (wcfB) of Bacteroides fragilis are obtained through bioinformatics analysis and mining, mutants are constructed through point mutation and combinatorial mutation, and the ability of the mutants to catalytically produce 2 '-FL is verified in Escherichia coli Nissle 1917. According to the alpha-1, 2-fucosyltransferase mutant obtained through screening, the yield of 2 '-FL is increased by 20% or above compared with the yield of a wild original recombinant strain, and the yield of the highest M51 is increased by 93.1%. The transformation strategies provided by the invention provide important theoretical and technical support for the alpha-1, 2-fucosyltransferase in the industrial production of breast milk oligosaccharides such as 2 '-FL and the like.

The invention belongs to the technical field of microbial genetic engineering and protein delivery, and particularly relates to an engineered bacterial secretion system for efficiently delivering protein and application of the engineered bacterial secretion system. Specifically, on the basis of analyzing a delivery mechanism of bacteroides fragilis GS086 type double-effect protein T6SS, engineering modification is performed on a toxic structural domain of the effect protein, and a bacterial secretion system capable of efficiently and simultaneously delivering a plurality of proteins is constructed. According to the system, a modified strain is a natural human intestinal symbiotic bacterium, the problems of high immunogenicity, poor stability and the like are effectively avoided, and protein can be delivered in situ in the intestinal tract to realize precise regulation and control of an intestinal flora structure and secretion of specific target protein, so that the system has a good practical application value.

This invention discloses a monoclonal antibody against a Bacteroides fragilis-specific protein and its applications, belonging to the field of biotechnology. Using the OmpA and SusD proteins on the surface of Bacteroides fragilis as immunogens, this invention prepares a highly specific monoclonal antibody with strong antigen-binding affinity using hybridoma technology. After conjugating this monoclonal antibody with magnetic beads, the resulting magnetic bead antibody conjugate can efficiently enrich and / or isolate Bacteroides fragilis from treated samples, offering advantages of convenience and low cost. Furthermore, the isolated Bacteroides fragilis can be used for whole-genome sequencing, metabolite analysis, and strain function research, providing new technical means for Bacteroides fragilis microecological research, probiotic preparation quality control, rapid clinical diagnosis, and functional strain screening.

The invention relates to the technical field of microorganisms, in particular to application of Bacteroides fragilis in preparation of a product for preventing or treating chicken testis blood testis barrier injury. The invention discloses application of Bacteroides fragilis in preparation of products for preventing or treating chicken testis blood-testis barrier injury for the first time, and experiments prove that the Bacteroides fragilis can improve the weight of chicken testis, the diameter and area of the testis, the number of spermatogonial stem cells in the testis and the expression level of testis blood-testis barrier related protein, and can be used for preparing a product for preventing or treating chicken testis blood-testis barrier injury. The completeness and functions of chicken testis cells can be maintained, and the normal development of the testis can be promoted. The application of the Bacteroides fragilis in the field of reproductive development of chickens is beneficial for promoting the breeding industry to develop towards a more efficient and sustainable direction.

The invention belongs to the technical field of polysaccharide vaccine vector synthesis, and relates to a pentasaccharide repeating unit and decasaccharide repeating unit compound of zwitterionic polysaccharide PS A2 and a synthesis method thereof. The PS A2 pentasaccharide repeating unit is successfully synthesized through a [2 + 2 + 1] strategy, and the technical problems of construction of a mannoheptaose C6-position ether bond, determination of a side chain methyl configuration, efficient construction of a 1, 2-cis-glucosidic bond, synthesis of multiple amino sugars and the like in the synthesis process are solved. The pentasaccharide repeating unit is coupled with other compounds and can be used for researching the potential anticancer effect of the PS A2. The pentasaccharide repeating units with different chiral methyl groups on the side chains provided by the invention can be used for subsequently performing activity screening on the two pentasaccharide repeating units to compare the influence of different methyl chirality on antigenicity, so that a foundation is laid for bacteroides fragilis sugar vaccines; the decasaccharide repeating unit provided by the invention provides a new path for synthesizing long-chain zwitterionic polysaccharide PS A2.

Different animal colitis model tests prove that the bacteroides fragilis, especially the inactivated bacterial liquid and inactivated bacterial powder of the bacteroides fragilis ZY-312 with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.10685, have the effects of improving and treating infectious enteritis and non-infectious enteritis. The inactivated bacteroides fragilis powder with the complete form, provided by the invention, has a good effect on improving non-infectious enteritis and colitis under different concentration formulas, has no side effects on organisms, and has very good edible and application prospects.

The invention relates to the technical field of biology, in particular to bacteroides fragilis FMBL Ba24006 DMX for metabolism of pectic polysaccharides and application, the bacteroides fragilis FMBL Ba24006 DMX is preserved in China Center for Type Culture Collection on January 20, 2026, the preservation number is CCTCC M 2026175, the bacteroides fragilis FMBL Ba24006 DMX has good pectin metabolism capacity, pectin can be effectively used as a carbon source to achieve rapid proliferation, and meanwhile, the bacteroides fragilis FMBL Ba24006 DMX can be used for metabolism of pectic polysaccharides. The bacterial strain has a good antibacterial effect on hemorrhagic Escherichia coli; the compound is sensitive and moderately sensitive to cefoxitin and rifampicin. The strain can produce a large amount of short-chain fatty acid when being used for fermenting pectin, and fermentation liquor taking the pectin as a carbon source has relatively strong scavenging capacity on DPPH and ABTS free radicals; a relatively good inhibition effect is achieved on the activity of alpha-amylase; the method can be used for preparing antioxidant products, fermented foods, health-care products, food additives and feeds, and has a wide application prospect.

The invention discloses a composition, a kit and a detection method for detecting bacterial infection pathogens. The composition comprises at least one of a component A, a component B and a component C, the component A comprises nucleotide sequences as shown in SEQ ID NO: 1-3, and the component A is used for detecting bacteroides fragilis; the component B comprises nucleotide sequences as shown in SEQ ID NO: 4-6, and the component B is used for detecting citrobacter freundii; the component C comprises nucleotide sequences as shown in SEQ ID NO: 7-9, and the component C is used for detecting enterobacter aerogenes. By designing the upstream and downstream primers and the corresponding probes, the composition for detecting the bacterial infection pathogens can detect and distinguish at least one of bacteroides fragilis, citrobacter freundii and enterobacter aerogenes, is high in sensitivity, high in specificity and strong in anti-interference performance, improves the detection efficiency, shortens the detection period, reduces the detection cost, and is suitable for popularization and application. Good application prospects are realized.

The invention belongs to the technical field of disease prognosis and molecular biology, and relates to a flora marker for colorectal cancer liver metastasis diagnosis and liver metastasis risk assessment and application of the flora marker. The marker comprises the following three strains: bifidobacterium bifidum, bacteroides fragilis and bacteroides heparinidolyticus. The method comprises the following steps: acquiring information of microorganisms in excrement of a patient through a high-resolution metagenomics detection technology; a random forest algorithm is utilized to construct a colorectal cancer liver metastasis classification model based on the flora markers, the model can distinguish people without colorectal cancer metastasis and people with liver metastasis and accurately predict high-risk patients with colorectal cancer liver metastasis, and the effect of the model is superior to that of a clinical conventional tumor serum marker. The kit has the advantages of noninvasive detection and high accuracy, and can provide a reliable tool for liver metastasis diagnosis and individualized prognosis management of colorectal cancer patients.

Provided in the present application are a real-time quantitative detection method for next-generation probiotics on the basis of flow cytometry and the use thereof. The next-generation probiotics comprise Akkermansia muciniphila and / or Bacteroides fragilis. In the present application, flow cytometry is used in the detection of next-generation probiotics to provide quantitative data of viable and non-viable cells in real time, thereby rapidly completing the high-throughput detection of viable cells in a sample while reducing the risk of contamination during the detection process. Moreover, the detection method can also detect next-generation probiotics that are unculturable due to insufficient metabolic activity, offering rapid detection speed and high accuracy.

The invention provides difunctional tremella polysaccharide as well as a preparation method and application thereof, the tremella polysaccharide is prepared by adopting a water extraction method, and the steps of crushing and sieving, hot water extraction, centrifugal separation, vacuum concentration, alcohol precipitation, Sevag deproteinization, dialysis, acidolysis, dialysis and freeze drying are performed. The trifluoroacetic acid degradation method has the characteristics of rapidness, high efficiency, simplicity and easiness in operation, the neutral sugar content of the prepared tremella polysaccharide is greater than or equal to 74%, the uronic acid content is greater than or equal to 21%, and the purity is greater than or equal to 96%. The difunctional tremella polysaccharide can significantly promote proliferation and secretion of nitric oxide NO of RAW264.7 macrophages, and significantly promote proliferation of bacteroides multiforme, bacteroides simplex, bacteroides ovale, bacteroides fragilis, bifidobacterium longum subsp. Longum, bifidobacterium breve, bacteroides bacteria, bifidobacterium bacteria and mixed bacteria. The compound has the advantages of being high in purity, activating macrophages and promoting probiotic proliferation, and can be applied to food and health care products.

The invention discloses application of bacteroides fragilis in preparation of a medicine for preventing and / or treating porcine intestinal coronavirus infection. The research finds that bacteroides fragilis hydrolyzes bound bile acid through bile salt hydrolase (BSH) to generate free bile acid (such as lithocholic acid LCA and deoxycholic acid DCA), so that an antiviral effect is generated. The bacteroides fragilis can regulate bile acid metabolism through BSH enzyme activity to inhibit virus infection, which indicates that the bacteroides fragilis can be used for preventing or treating porcine intestinal coronavirus infection.